Phototherapy for Shift Work Sleep Disorder
(SHIFT Trial)
Trial Summary
What is the purpose of this trial?
The purpose of this study is to examine the effectiveness of a personalized light exposure schedule for Shift Work Disorder (SWD) in night shift workers compared to a non-personalized light exposure schedule.
Do I need to stop taking my current medications for the trial?
The trial excludes participants using medications that impact central nervous system functioning, so you may need to stop taking such medications.
What data supports the idea that Phototherapy for Shift Work Sleep Disorder is an effective treatment?
The available research shows that phototherapy can effectively reduce sleepiness and adjust the sleep schedule for shift workers. A meta-analysis found that medium-intensity light therapy for a short time at night helps reduce sleepiness, while high-intensity light therapy helps shift the sleep schedule to better match the work hours. This suggests that phototherapy can help shift workers feel more awake and align their sleep patterns with their work schedule.12345
What safety data exists for phototherapy in treating sleep disorders?
Phototherapy, also known as light therapy, has been studied for its safety and efficacy in treating circadian rhythm sleep disorders. Safety concerns primarily involve potential ocular risks, as light can affect retinal structure and physiology. Recommendations include using lamps that avoid harmful spectral emissions, standardized therapy fixtures, and monitoring by ophthalmologists for patients with eye conditions. For those with healthy eyes, optometrist supervision is advised for extended treatments. Phototherapy should be avoided in patients with retinal disorders, and consultation with an ophthalmologist is recommended.34678
Eligibility Criteria
This trial is for night shift workers who've been on this schedule for at least 6 months and have Shift Work Disorder based on ICSD-3 criteria. They must work a minimum of two night shifts per week, starting between 6 PM and 2 AM, lasting from 8 to 12 hours. Pregnant individuals, those with other sleep disorders or unstable major medical conditions, heavy tobacco users, and people using certain drugs are excluded.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Pre-treatment Assessment
27-hour laboratory visit for pre-treatment assessment of DLMO with hourly saliva melatonin samples
Treatment
Participants follow light exposure recommendations from the SHIFT mobile application for two weeks
Follow-up
Participants are monitored for insomnia and daytime sleepiness post-treatment
Treatment Details
Interventions
- Phototherapy
Phototherapy is already approved in European Union, United States, Canada, Japan, China, Switzerland for the following indications:
- Psoriasis
- Eczema
- Vitiligo
- Neonatal Jaundice
- Seasonal Affective Disorder
- Psoriasis
- Eczema
- Vitiligo
- Neonatal Jaundice
- Seasonal Affective Disorder
- Shift Work Disorder
- Psoriasis
- Eczema
- Vitiligo
- Neonatal Jaundice
- Seasonal Affective Disorder
- Psoriasis
- Eczema
- Vitiligo
- Neonatal Jaundice
- Psoriasis
- Eczema
- Vitiligo
- Neonatal Jaundice
- Psoriasis
- Eczema
- Vitiligo
- Neonatal Jaundice
- Seasonal Affective Disorder
Find a Clinic Near You
Who Is Running the Clinical Trial?
Henry Ford Health System
Lead Sponsor
American Academy of Sleep Medicine
Collaborator